Your browser doesn't support javascript.
loading
Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report.
Rossi, Luigi; Cimino, Giuseppe; Gozzi, Elisa; Sinjari, Marsela; Brandi, Martina; Ceddia, Serena; Cosimati, Antonella; Raimondi, Lucrezia; Fontana, Antonella; Filippi, Luca; Bagni, Oreste; Spinelli, Gian Paolo.
Affiliation
  • Rossi L; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Cimino G; Department of Cellular Biotechnology and Hematology, University of Rome "Sapienza", Rome, Italy.
  • Gozzi E; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Sinjari M; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Brandi M; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Ceddia S; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Cosimati A; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Raimondi L; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
  • Fontana A; Department of Radiotherapy, Santa Maria Goretti Hospital, Latina, Italy.
  • Filippi L; Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.
  • Bagni O; Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.
  • Spinelli GP; UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
Case Rep Oncol ; 14(1): 634-640, 2021.
Article in En | MEDLINE | ID: mdl-33976646
ABSTRACT
We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: Case Rep Oncol Year: 2021 Type: Article Affiliation country: Italy
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: Case Rep Oncol Year: 2021 Type: Article Affiliation country: Italy